Thiogenesis Therapeutics, Corp. TTI.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -4.71M | -5.01M | -5.33M | -4.89M | -3.64M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 452.20K | 552.10K | 556.60K | 579.70K | 390.70K |
| Change in Net Operating Assets | -601.30K | 186.60K | 437.40K | 960.00K | 829.80K |
| Cash from Operations | -4.86M | -4.27M | -4.34M | -3.35M | -2.42M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 12.19M | 3.81M | 3.81M | 4.07M | 260.90K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 8.82M | 2.77M | 2.77M | 2.95M | 186.50K |
| Foreign Exchange rate Adjustments | -22.60K | -9.70K | -8.00K | -32.90K | -8.50K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3.94M | -1.51M | -1.58M | -436.50K | -2.24M |